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Background: Rising healthcare costs motivate continued cost-reduction efforts. To help
lower costs associated with open-angle glaucoma (OAG), a prevalent, progressive disease
with substantial direct and indirect costs, clinicians need to understand the cost-effectiveness
of intraocular pressure (IOP)-lowering pharmacotherapies. There is little published informa-
tion on clinicians’ knowledge and attitudes about cost-effectiveness in glaucoma treatment.
Purpose: This pilot focus group study aimed to explore clinician attitudes and perspectives
around the costs and cost drivers of glaucoma therapy; the implementation of cost-
effectiveness decisions; the clinical utility of cost-effectiveness studies; and the cost-
effectiveness of available treatments.
Methods: Six US glaucoma specialists participated in two separate teleconferencing ses-
sions (three participants each), managed by an independent, skilled moderator (also
a glaucoma specialist) using a discussion guide. Participants reviewed recent publications
(n=25) on health economics outcomes research in glaucoma prior to the sessions.
Results: Participants demonstrated a clear understanding of the economic burden of glaucoma
therapy and identified medications, diagnostics, office visits, and treatment changes as key cost
drivers. They considered cost-effectiveness an appropriate component of treatment decision-
making but identified the need for additional data to inform these decisions. Participants
indicated that there were only a few recent studies on health economics outcomes in glaucoma
which evaluate parameters important to patient care, such as quality of life and medication
adherence, and that longitudinal data were scant. In addition to efficacy, participants felt patient
adherence and side-effect profile should be included in economic evaluations of glaucoma
pharmacotherapy. Recently approved medications were evaluated in this context.
Conclusion: Clinicians deem treatment decisions based on cost-effectiveness data as clini-
cally appropriate. Newer IOP-lowering therapies with potentially greater efficacy and favor-
able side-effect and adherence profiles may help optimize cost-effectiveness. Future studies
should include: clinicians’ perspectives; lack of commercial bias; analysis of long-term
outcomes/costs; more comprehensive parameters; real-world (including quality-of-life)
data; and a robust Markov model.
Keywords: open-angle glaucoma, ocular hypertension, cost-effectiveness, clinician
knowledge and attitudes, focus group, prostaglandin analogs
Introduction
Glaucoma, the leading cause of irreversible blindness globally, is increasing in
prevalence due to rapid increase in the aging population.1,2 An estimated
64.3 million people (aged 40 to 80 years) globally were affected by glaucoma in
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2013, and that number is expected to reach 76 million by
2020.2 Open-angle glaucoma (OAG) accounts for more
than 70% of all glaucoma cases.3 The number of
Americans living with OAG—which is a chronic, progres-
sive disease—was estimated to be 2.7 million in 2011 and
projected to reach 7.3 million in 2050, growing at a rate of
28% per decade.4
Glaucoma decreases health-related quality of life; the
extent of the reduction is directly associated with the
severity or stage of the disease.5–7 Patients with glau-
coma are faced with the difficult challenges of visual
dysfunction in everyday life, such as reduced mobility
and difficulty with reading. Among those with glaucoma,
self-reported visual disability is associated with difficulty
walking, falls, and depression. As the disease progresses,
the psychological burden of vision loss increases.8
Besides the affected individual, blindness and visual
impairment from glaucoma also impact the families, the
healthcare system, and society in general, creating
a substantial socioeconomic burden.7
The annual medical cost of glaucoma and disorders
of the optic nerve in the US was estimated at
$6.1 billion in 2014 and projected to be as high as
$12 billion by 2032 and $17.3 billion by 2050.9 The
true direct cost would be considerably higher if all
patients with this heavily underdiagnosed disease were
treated.7,10 A retrospective cohort analysis of Medicare
claims found that glaucoma patients with any degree of
vision loss had 46.7% higher total costs compared with
those without vision loss, with mean total annual med-
ical costs increasing from $8157 for no vision loss to
$18,670 for blindness.11 A Markov model replicating
health events over the remaining lifetime of a patient
with newly diagnosed glaucoma on US Medicare claims
data from 1999 to 2005 estimated that the average life-
time cost of care for people with primary OAG (POAG)
was about $137 per patient per year, or $1688 greater
than those without glaucoma.12 Using a large, nationally
representative sample of Medicare beneficiaries, a recent
study found that patients with glaucoma incurred an
additional $2903 annual total health care costs and
$2599 higher non-outpatient costs (total health care
costs with the exclusion of outpatient payments) com-
pared with those without.8
The cost of glaucoma care in the US, then, is high
and expected to become higher as the prevalence of the
disease increases. In order to lower those costs, stake-
holders—including clinicians—need to better understand
the cost-effectiveness of IOP-lowering therapies. Cost-
effectiveness data provide information about the costs of
different interventions or treatment strategies relative to
their performance, which can be helpful in identifying
potential ways to reduce the economic burden of treat-
ment. Over the past decade, research has begun to
address cost-effectiveness in the treatment of OAG and
ocular hypertension (OHT).13–16
While awareness of costs is of increasing importance,
little is known about whether and how clinicians treating
glaucoma patients use cost-effectiveness in clinical deci-
sion-making. We convened a small focus group of glau-
coma specialists to learn more about their knowledge and
attitudes regarding cost-effectiveness in the treatment of
patients with OAG or OHT. The focus group method’s
main advantage is its qualitative nature, which is com-
plementary to that of quantitative research and allows in-
depth exploration of thoughts, attitudes, and opinions via
open-ended questions. It is commonly used to gain origi-
nal insights and perspectives, uncover opinion trends,
deepen understanding, and develop new hypotheses or
ideas for further research. The aim of this pilot focus
group study was to: 1) explore clinician perspectives
regarding the costs and cost drivers of glaucoma ther-
apy; 2) explore clinician attitudes and experience regard-
ing the implementation of cost-effective decisions when
treating patients with OAG or ocular hypertension
(OHT) and the clinical utility of cost-effectiveness stu-
dies; and 3) explore clinician views about the cost-effec-
tiveness of available treatment strategies and modalities
for OAG and OHT and identify potential opportunities to
improve glaucoma pharmacotherapy and reduce costs.
Methods
A focus group was formed to include six academic
glaucoma specialists recognized as leading experts in
the field of glaucoma treatment. Two separate telecon-
ference sessions, each with three participants and led by
the same moderator (also a glaucoma specialist) were
conducted.
A discussion guide was created and distributed
beforehand to the participants in order to facilitate
and focus the discussion sessions. The discussion
guide comprised a mixture of standardized/ranked and
open-ended questions, which were grouped under the
following general topics: the cost of care, cost consid-
erations, current medical glaucoma therapies, and
health economics and outcomes research (HEOR)
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(Figure 1). To help address the specific questions about
HEOR in glaucoma, participants were asked to review
the summaries of 25 recent publications on health
economics of glaucoma therapies prior to the telecon-
ferences (Table 1).
Sessions spanned 2 h to allow the moderator ample
time to solicit responses from participants to standar-
dized/ranked questions, and to allow for additional
discussion around open-ended questions. Following
the conclusion of the discussion sessions, responses
of the participants to open-ended questions were sum-
marized descriptively based on the teleconference tran-
scripts. Where possible, ranked responses were tallied.
Because the discussions were based on existing pub-
lished literature and general clinical experiences and no
research was performed on human or animal subjects,
human cell lines, or human tissues, this study did not
require ethics committee approval.
Results
Costs and Cost Drivers in Glaucoma
Therapy
Participants noted that medical costs, including the finan-
cial burden of glaucoma therapy, are rising. They asserted
the need to reduce that cost so that it is possible for
clinicians to continue to provide their patients the best
care. When asked to define “cost,” they noted that the
economic implications of glaucoma extend well beyond
the direct, short-term costs to the patient or health system.
Some specifically stated that, apart from expenses for
medical services including medications, office visits, diag-
nostic testing, and surgery, glaucoma also produces sig-
nificant patient-based and societal costs in forms of
productivity/income loss or expenses for assistance with
daily living, ie, the long-term cost of vision loss.
Participants acknowledged that there are multiple cost
drivers in glaucoma care. The drivers identified as having
significant cost impact included medications, diagnostics,
office visits, and treatment change (either switching med-
ications or adding another agent, or advancement to laser
or incisional surgery). Changes in treatment, the group
noted, increase cost by adding office visits and patient
time. Estimates of the contribution of medication cost to
the overall cost of glaucoma care varied from 20% to 40%
among the participants—and was perceived as a greater
proportion of the cost relative to laser treatment and sur-
geries, especially among well-controlled patients.
Meanwhile, more than one participant noted that treat-
ment costs are directly related to disease stage and the
number of different treatments required. For OAG patients
who are diagnosed and treated early, the greatest part of
expenditure will most likely be on medication, these par-
ticipants stated. However, they noted, for those patients
who have more advanced disease when diagnosed, whose
pressure is poorly controlled, and who require more inter-
ventions (multiple medications, even multiple surgeries),
the overall cost will almost certainly be higher and likely
be led by costs of surgical care and productivity losses.
Cost Considerations in Glaucoma
Therapy
Participants acknowledged that patients’ access to pre-
scription medications is a major concern and influenced
primarily by price and health insurance status. They stated
that out-of-pocket cost to patients is an important consid-
eration in their practice; indeed, a significant reason whyFigure 1 Topics discussed in focus groups of glaucoma specialists.
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Table 1 Key HEOR Articles Identified Through Literature Search*
Lead Author,Year Article Title
Berenson, 201152 Cost-offset analysis: bimatoprost versus other prostaglandin analogues in open-angle glaucoma
Bernard, 200346 Clinical and economic impacts of latanoprost 0.005% in first-line treatment of open-angle glaucoma and ocular hypertension in
France
Bhosle, 200717 Medication adherence and health care costs with the introduction of latanoprost therapy for glaucoma in a Medicare managed care
population
Cantor, 200818 Economic evaluation of medication, laser trabeculoplasty and filtering surgeries in treating patients with glaucoma in the US
Costagliola, 200319 Assessing the cost-effectiveness of switching from a beta-blocker to latanoprost in the treatment of ocular hypertension
Day, 200447 A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular
hypertension
De Natale, 200920 Cost effectiveness of travoprost versus a fixed combination of latanoprost/timolol in patients with ocular hypertension or
glaucoma: analysis based on the UK general practitioner research database
Denis, 200821 Costs and persistence of alpha-2 adrenergic agonists versus carbonic anhydrase inhibitors, both associated with prostaglandin
analogues, for glaucoma as recorded by The United Kingdom General Practitioner Research Database
Fiscella, 200622 Estimated comparative costs of achieving a 20% reduction in intraocular pressure with bimatoprost or latanoprost in patients with
glaucoma or ocular hypertension
Frenkel, 200723 Pharmacoeconomic analysis of prostaglandin and prostamide therapy for patients with glaucoma or ocular hypertension
Fristrom, 201024 A randomized, 36-month, post-marketing efficacy and tolerability study in Sweden and Finland of latanoprost versus non-
prostaglandin therapy in patients with glaucoma or ocular hypertension
Goldberg, 200625 Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of
bimatoprost compared with other medications
Holmstrom, 200626 The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries
Hommer, 200827 A cost-effectiveness analysis of fixed-combination therapies in patients with open-angle glaucoma: a European perspective
Lachaine, 200816 Prostaglandin analogues for ophthalmic use: a cost-effectiveness analysis
Noecker, 200628 Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications
Orme, 201229 Long-term medical management of primary open-angle glaucoma and ocular hypertension in the UK: optimizing cost-effectiveness
and clinic resources by minimizing therapy switches
Payet 200830 Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France
Prager, 20168 Self-reported function, health resource use, and total health care costs among Medicare beneficiaries with glaucoma
Schmier, 201457 Adjunctive therapy patterns in glaucoma patients using prostaglandin analogs
Seider, 201231 Cost of selective laser trabeculoplasty vs topical medications for glaucoma
Stein, 201245 Cost-effectiveness of medications compared with laser trabeculoplasty in patients with newly diagnosed open-angle glaucoma
Stewart, 200914,58 Cost-effectiveness of latanoprost and timolol maleate for the treatment of glaucoma in Scandinavia and the United Kingdom, using
a decision-analytic health economic model
van Gestel, 201248 The long-term outcomes of four alternative treatment strategies for primary open-angle glaucoma
Wong, 201332 An adherence based cost-consequence model comparing bimatoprost 0.01% to bimatoprost 0.03%
Notes: *A literature search was conducted in PubMed using the following search terms: cost-effectiveness; glaucoma medical treatment; health economics outcomes research
glaucoma; glaucoma prostaglandin analogs cost-effectiveness; intraocular pressure-lowering glaucoma cost-effectiveness; open-angle glaucoma cost burden; open-angle glaucoma
pharmacoeconomics; glaucoma care cost burden. The search was limited to English-language articles published within the past 15 years. Primary health economic research studies
concerningmedical glaucoma therapy, especially prostaglandin analogs (PGAs), and narrative or systematic review articles on glaucoma economics were identified, with priority given to
those publishedmore recently and/or involving some of our potential participants as authors and those that took place in the US and Europe. Selected references were reviewed by the
focus group moderator to ensure that key publications have been taken into account.
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a generic prostaglandin analog (PGA) is the first-choice
monotherapy for the majority of their glaucoma patients is
insurance coverage. They further noted that efficacy, ocu-
lar and/or systemic side effects, dosing convenience, and
patient adherence are the main factors that influence treat-
ment choices, first or second line. Patient preferences also
play a role, with many patients holding strong preferences
among available treatment options. Patient perceptions or
attitudes about generic substitutions, for example, can vary
widely. The participants stated that many of their patients
simply opt for the least costly alternative, while others
place the highest value on clinical outcomes and are there-
fore willing to pay or tolerate more adverse effects for
therapies with greater efficacy.
Participants added that, in reality, clinicians are often
unaware of medications’ actual costs to patients. One
noted that he prescribes mainly based on efficacy at least
in part because it has become very difficult in the past few
years to decipher the costs of medications charged at
individual pharmacies.
Although the clinicians in this focus group generally do
not view themselves as gatekeepers for the healthcare
system, they were in agreement that cost is an important
consideration in the management of glaucoma from the
broader perspective of society. One of the participants
specifically noted that, beyond a responsibility to patients,
clinicians also have a responsibility to society. He pointed
out that clinicians should keep in mind their obligation of
being a good steward of societal dollars and healthcare
resources when making treatment decisions.
Cost-Effectiveness of Current Medical
Therapies
All participants agreed that PGAs, the most widely used
first-line glaucoma medications, stand out as a cost-
effective treatment among all available IOP-lowering med-
ications. The drug class was described as efficacious
(reaching a target IOP reduction of 30% most of the
time), long-lasting in efficacy (which translates into less
frequent visits and thus cost savings), safe (least number of
systemic adverse events), time-tested (on the market more
than 20 years), dosed conveniently at once daily, and
reasonably priced in an era of generics. However, some
participants cautioned that generics are not all created
equal—their experiences indicate that the variability in
efficacy and tolerability is significant between different
generic brands.
Participants stated that first-line treatment with a PGA
is efficacious in lowering IOP in the majority of patients
with glaucoma and that only a small minority require an
alternative therapy. However, they also noted that, from
a longitudinal perspective, combination therapy is often
necessary to achieve or maintain target IOP, and that
medication switching due to reasons such as tachyphy-
laxis, side effects, and visual field progression is common
despite treatment. One participant estimated that at least
80% of patients with moderate to advanced disease and
possibly 20% of patients with early disease require adjunc-
tive therapy. The general consensus among the clinicians
was that newer agents with greater efficacy than current
regimens are needed in order to better control the cost of
glaucoma therapy. If most patients will require adjunctive
therapy at some point—and if, as noted above, treatment
changes increase the cost by adding office visits and
patient time—then having better first- or second-line treat-
ments should provide long-term cost savings.
The approach to adjunctive therapy varied among par-
ticipants. The majority reported that they typically choose
to add a second drug when PGA monotherapy is insuffi-
cient. Their add-on choices usually include a topical car-
bonic anhydrase inhibitor (CAI) or a beta-blocker. Some
noted that they tend to switch medication when there is an
inadequate initial response and may consider laser surgery
earlier in some cases to avoid polypharmacy. While spe-
cific adjunctive intervention varies, the general consensus
was that an optimal second-line therapy is still lacking.
Two participants suggested that an alternative to adding
a second drug is switching the initial PGA (typically
generic latanoprost) to the NO-donating PGA latanopros-
tene bunod (LBN) 0.024%—the latter is as well tolerated
and safe as latanoprost but has the potential to provide
additional pressure-lowering.33 Latanoprostene bunod was
approved by the FDA in late 2017 and represents the first
new PGA in more than 5 years, as well as the first NO-
donating PGA.34 One participant mentioned that he is
considering the Rho kinase (ROCK) inhibitor netarsudil
0.02% as a second-line choice, another recently approved
therapy, although it must be used in combination with
another IOP-lowering medication, such as a PGA, in
order to provide additional reductions in IOP over the
standard of care; in addition, concerns about relatively
high hyperemia rates exist with netarsudil.35
When asked what is needed in a new medication to
make it cost-effective, participants responded that new
drugs need to be significantly better than the current
Dovepress Feldman et al
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options in one or several ways: efficacy, tolerability, safety,
duration of action, or any combination thereof. In addition,
participants asserted that adherence is an important con-
sideration in determining whether a glaucoma medication
is cost-effective. As one of them pointed out, no therapy
can be cost-effective if the patient is non-adherent. Thus,
a new medication may initially cost more, but if patients
take it as prescribed, the increase in adherence may justify
the cost over the long run. Participants emphasized that
glaucoma is a chronic disease associated with low medica-
tion adherence in general and noted that improvement in
adherence is critical for better management of the disease.
Indeed, when asked to rank the importance of adherence
improvement in the management of glaucoma on a rank
scale of 1 to 5 (with 1 being “not important” and 5 being
“very important”), the responses were 4 or 5. One partici-
pant remarked that adherence is one of the greatest unmet
needs in glaucoma pharmacotherapy. Furthermore, partici-
pants viewed adherence as a multifactorial issue and iden-
tified the following factors as the main barriers to
adherence in glaucoma therapy: side effects, number of
drops, costs, and patient understanding of the disease.
The Utility of Cost-Effective Research
Participants were unanimous in their view that, overall,
current cost-effectiveness research offers little clinical uti-
lity for the treatment of glaucoma or OHT. The group
noted that published cost-effectiveness studies in the field
of glaucoma have largely been geared towards insurers,
payers, and pharmacy benefit managers, rather than doc-
tors. They felt that few of the studies looked at parameters
that are important to patient care and clinical practice, such
as quality of life and medication adherence; and that long-
itudinal data are scant, with a dearth of evidence to deter-
mine what the most cost-effective treatment algorithm is
over a patient’s lifetime.
Responses to the ranking question “How much does
HEOR research influence your thinking about IOP-
lowering treatment?” were 1 to 2 (on a rank scale of 1 to
5, with 1 being “no influence” and 5 being “enormous
influence.") indicating that the influence of current cost-
effectiveness data on clinical decision-making is indeed
minimal. Participants stated that the available data may be
used to guide insurers and payers but would need to be
more persuasive and better designed in order to guide
clinicians. Several participants commented that they find
being good stewards of resources for the health care sys-
tem as a whole an important goal but difficult to achieve
given the current knowledge base about cost-effectiveness
and payer-based variability in drug pricing.
According to participants, desirable elements of future
economic studies in glaucoma pharmacotherapy include:
a clinician’s perspective; an independent approach (ie,
without commercial bias); analysis of long-term treatment
outcomes and costs; a more comprehensive set of para-
meters, including stage of disease, treatment switch or
addition, adherence, side effects associated with various
therapies; real-world data related to clinical practice,
including quality-of-life data; and a robust Markov
model that allows assessment of all the costs.
Participants asserted that cost-effectiveness should be
considered in the context of the patient’s age and expected
lifespan, and, if possible, it would be important to deter-
mine the incremental cost of every additional mm Hg of
IOP reduction.
Discussion
The cost-effectiveness of care is becoming an increasingly
important aspect of glaucoma therapy because of the
growing patient population and associated cost increases.
Some prior research has investigated the economic out-
comes of various glaucoma treatments, but few if any past
studies have sought to identify clinicians’ views regarding
cost-effectiveness and their attitudes and experience using
cost-effective data in the treatment of glaucoma.
Participants in the present study displayed a consistent
understanding of the economic impact of glaucoma and
the need to reduce treatment costs. Their perception that
medication use contributes substantially to costs is consis-
tent with previous reports that prescription medication
costs drive financial burden at all stages of glaucoma and
are equal to or greater than all other charges.36–40 There is
also evidence in support of participants’ impression that
diagnostics are a significant cost driver. In a recent study
among Medicare beneficiaries, diagnostic testing accounts
for about one-third of glaucoma-related costs (excluding
medication cost).41
There is abundant evidence from previous quantitative
studies supporting participants’ assertion that disease
severity has a direct impact on the costs of glaucoma.
According to a US study, annual direct medical costs for
patients with early glaucoma, advanced glaucoma, and
end-stage glaucoma averaged $623, $1915, and $2511,
respectively.36 European studies have reported similar
findings. Resource utilization and direct medical costs
increase as disease worsens, and medication costs ranged
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from 42% to 56% of direct costs at each disease stage.40 In
a German cross-sectional study examining treatment costs
of OHT and POAG, average total annual direct costs per
patient were €226 for OHT, €423 for early POAG, €493
for moderate POAG, and €809 for advanced POAG.42
Among patients with early glaucoma, medication costs
comprise most of the cost of care.39,42 For those with
advanced disease, indirect costs such as costs for home
health care and rehabilitation become predominant.43,44
The finding that many of the participants give consid-
erable thought to cost—specifically fees charged to
patients—in their prescribing decisions (in the context of
ensuring efficacy) suggests that awareness of drug cost to
patients is fairly high among prescribing clinicians.
However, the results of the present study also suggest
that some barriers exist to implementing cost-
effectiveness decisions in the treatment of glaucoma. As
the group noted, cost information for medications is often
not readily accessible. This is not surprising, given that
multiple middlemen (insurers, manufacturers, and phar-
macy benefit managers) are involved in establishing drug
prices. Without knowing what a drug’s actual price is at
the pharmacy, it is difficult for clinicians to base decisions
on costs.
Additionally, clinical decision-making that aims to
reduce cost requires the guidance of research showing
the relative cost-effectiveness of therapeutics and treat-
ment strategies, but such evidence is largely lacking in
the literature. Based on their own experience and a review
of select economic studies in the field, this group of
glaucoma specialists was of the opinion that there is
a shortage of solid, useful data on cost-effectiveness of
glaucoma therapies in the present literature. Major ques-
tions—such as how cost-effective a particular medication
is compared to other treatment modalities such as laser
trabeculoplasty or surgery and which medication is most
cost-effective in lowering IOP—still lack a definite
answer, although some evidence exists suggesting that
first-line PGA monotherapy provides greater value than
laser trabeculoplasty assuming optimal medication adher-
ence and is the more cost-effective treatment compared to
other types of available glaucoma medications.16,45–48 This
highlights the need for unbiased, well-designed economic
studies to establish the relative cost-effectiveness and
impact on quality of life of the treatment regimens for
OAG or OHT and to identify opportunities for further
savings.
Since individual and societal economic burdens of
glaucoma both increase with disease severity, early identi-
fication and effective treatment of patients may help
reduce the overall costs.7 In support of this concept,
a French study modeling the lifetime treatment cost in
glaucoma showed that initial treatment with the most
effective drug would reduce medical and social costs.49
Currently, PGAs are widely preferred as the first-line
treatment for OAG or OHT. Highly effective in IOP-
lowering and available in generic forms, PGAs are con-
sidered to be an overall cost-effective treatment option.
Even so, as this group’s clinical experience indicates,
many patients do not achieve adequate IOP-lowering
with available agents and require further interventions,
increasing the cost of the disease. While cost-
effectiveness information on the two latest additions to
the treatment options for glaucoma—LBN and netarsudil
—is currently lacking, there is clearly a need for more
cost-effective IOP-lowering medications (Table 2).
In reality, prices for new medications are relatively
high, but price alone does not determine whether or not
a treatment is cost-effective. Any economic assessment of
a new treatment must also take into account the other
determinant of its cost-effectiveness: the clinical benefits
it provides, which may translate to savings in other cate-
gories of care. As pointed out by participants of this study,
a new medication can be cost-effective as long as it pro-
vides enough “added value” for which patients and the
society are willing to pay.
One medication that participants discussed in this con-
text was LBN 0.024%, the NO-donating PGA approved in
late 2017 for lowering IOP in patients with OAG or OHT.
LBN acts through its two metabolites—latanoprost acid
and an NO-releasing moiety (butanediol mononitrate)—
and lowers IOP by enhancing aqueous outflow through
both the uveoscleral and trabecular meshwork
pathways.50 The new drug appears to have all the impor-
tant therapeutic advantages of a first-line therapy: high
IOP-lowering efficacy, once-daily dosing, negligible sys-
temic side effects, and low rate of ocular hyperemia. In
a pooled analysis of the pivotal clinical trials, it was more
effective at lowering IOP than timolol 0.5% and safe and
well tolerated.51 Furthermore, LBN has been associated
with an IOP reduction of 1 to 1.5 mm Hg greater than that
of latanoprost 0.005% (Xalatan).33
An incremental improvement in efficacy, such as that
reported with LBN, could be fairly significant from the
cost-effectiveness standpoint. As mentioned, more
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effective lowering of IOP and the resulting decrease in the
risk of glaucoma progression itself could generate cost
savings from reduced health care resource utilization. In
a study using a cost-offset model to analyze the clinical
and economic outcomes of PGAs, an extra 1 mm Hg of
IOP reduction accounted for fewer cases of progression
and increased cost savings on office visits, visual field
tests, additional glaucoma medications, and surgeries
over a 7-year period.52 Further, when a monotherapy com-
bines greater efficacy with a once-daily regimen and
a tolerable side effect profile, treatment persistence may
improve, with less likelihood of medication addition or
switch and potentially better adherence. Poor adherence
to topical therapy is a well-established challenge in the
management of glaucoma patients.53,54 According to the
Glaucoma Adherence and Persistency Study, only 10% of
patients are continuously persistent with IOP-lowering
medications throughout a year, and, among the slightly
more than half of patients who restart after a gap in
refilling the prescription, nearly 80% will have at least
another gap.53 One possible barrier to adherence is the
use of adjunctive agents, which is required within a year
for adequate IOP control in about one-third of patients
starting glaucoma therapy and has been shown to contri-
bute to higher management costs.55–57,59 Side effects of
medications may also adversely impact adherence to
therapy.56,60
Netarsudil 0.02%, another new topical therapy that is
most recently available for reducing IOP in patients with
glaucoma or OHT, is a Rho kinase (ROCK) inhibitor. Like
LBN, netarsudil enhances trabecular outflow facility.35
The drug is thought to also decrease aqueous production
and episcleral venous pressure. Clinical trial data suggest
that netarsudil is not as effective as the PGAs, and that
more than half of patients experience conjunctival
hyperemia.35,61 As the most common side effect of topical
ocular prostaglandins, hyperemia in glaucoma patients has
been shown to be a major reason for medication changes
and result in increased overall treatment costs.59,62 Given
that it is conveniently dosed once-daily and no associated
systemic safety issues have been identified, however,
netarsudil could be potentially a more cost-effective
adjunctive option relative to the available alternatives.
Limitations of the present study include the small sam-
ple size (a single focus group of only six participants) and
the lack of participant diversity with regard to demo-
graphics and/or professional backgrounds. In particular,
the study included no input from comprehensive ophthal-
mologists or optometrists, who also manage glaucoma
patients in everyday practice. All the participants were
Table 2 Glaucoma Medications Approved in the US Since 2013
Medication Drug Classification Mechanism(s) of Action Key Benefits
Netarsudil, 0.02%* Rho kinase inhibitor Increase trabecular outflow -Negligible systemic side effects
-Dosed once daily
Latanoprostene
bunod, 0.024%
Nitric-oxide donating prostaglandin analog Increase uveoscleral and trabecular
outflow
-High IOP-lowering efficacy
-Favorable ocular and systemic
safety profile
-Dosed once daily
Brinzolamide/
brimonidine, 1%/
0.2%
Fixed combination (carbonic anhydrase
inhibitor/alpha-adrenergic agonist)
Decrease aqueous production and
increase uveoscleral outflow
-Possibly greater efficacy than
either component used as
monotherapy
-Fewer daily drops than
individual monotherapies
-Improved adherence
Dorzolomide/
timolol PF, 2%/0.5%
Fixed combination (carbonic anhydrase
inhibitor/beta-adrenergic antagonist)
Decrease aqueous production -Preservative-free
-Possibly greater efficacy than
either component used as
monotherapy
-Fewer daily drops than
individual monotherapies
-Improved adherence
Note: *A fixed-dose combination of netarsudil 0.02% and latanoprost 0.005% has become available since the focus group was convened.
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glaucoma specialists, whose patients are more likely to
have advanced disease and thus require special treatment
considerations. Although the group discussions yielded
meaningful data, the results may not be generalizable.
The majority of this group of glaucoma specialists said
that they discuss medication costs with their patients, for
example, but research indicates that cost-related conversa-
tions between ophthalmologists and glaucoma patients are
uncommon. In a recent study that analyzed 275 video-
recorded glaucoma office visits at six different medical
centers located in various geographic areas, only 87 visits
involved a discussion of medication cost.63
In summary, the present study provides new data on
glaucoma specialists’ knowledge and attitudes about cost-
effectiveness and cost-effectiveness research in glaucoma
therapy. The results suggest that these clinicians support
the incorporation of cost-effectiveness into treatment deci-
sions for glaucoma patients and are willing to provide care
proved to be cost-effective. A more robust evidence base
is needed to derive clear practical guidelines for decisions
based on cost-effectiveness. Newer IOP-lowering medica-
tions with the potential to provide clinically meaningful
benefit, such as LBN 0.024% and netarsudil 0.02%, or
a fixed-dose combination of netarsudil and latanoprost
approved for marketing after this focus group convened,
may be helpful in applying cost-effectiveness to the treat-
ment of OAG or OHT.
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